Researchers at Pitt have developed a flexible wireless sensor embedded intravaginal ring (FWS-IVR) for the on-demand electro-responsive release of anti-sexually transmitted infection (anti-STI) agents.
Description
Sexually transmitted infections (STIs) are a significant global health concern, affecting over 20 million new individuals each year in the US alone and resulting in an estimated $16 billion in direct medical costs. More than 30 million people live with human immunodeficiency virus (HIV) globally, with over 1 million new HIV infections occurring daily. To address this challenge, intravaginal drug delivery using intravaginal rings (IVRs) has emerged as an advantageous approach, as the vagina is the primary route of STI infection and IVRs can provide controlled, sustained release of anti-STI agents at the target site. While IVRs offer benefits over other intravaginal formulations, the continuous exposure to anti-STIs may not be ideal for healthy individuals seeking preventative measures. The researchers have therefore invented the FWS-IVR, which is designed to release anti-STI agents only when heterosexual intercourse occurs or at the user's intentional request. This is achieved through the integration of a flexible wireless sensor array that can detect changes in vaginal sodium and pH levels, which typically increase with the introduction of seminal fluid during intercourse.
Applications
Prevention of sexually transmitted infections
Advantages
FWS-IVR represents the first intravaginal device that combines wireless sensor technology, electro-responsive drug delivery, and on-demand release of anti-STI agents. This innovative approach has the potential to increase user convenience and control, while also improving the efficacy of STI prevention and management through targeted, responsive drug delivery. Further development and evaluation of the FWS-IVR could lead to significant advancements in the field of intravaginal health monitoring and drug delivery for the prevention and treatment of sexually transmitted infections.
Invention Readiness
This technology is at the level of in vitro data. The FWS-IVR utilizes a reservoir-type design, with the flexible wireless sensor array embedded within the IVR structure. The sensor array monitors the vaginal environment, triggering an electro-responsive drug release system when changes in sodium or pH levels are detected, indicating the need for anti-STI delivery. This system allows for on-demand, repeatable release of anti-STI agents, providing protection when necessary while avoiding continuous exposure. To enable the electro-responsive drug release, the researchers have developed a conductive polyurethane elastomer and incorporated betulinic acid-loaded polypyrrole nanoparticles into a semisolid matrix, which is then injected into the IVR reservoir between the conductive polymer-coated electrodes. This design allows for the controlled, electro-responsive release of the anti-STI agent upon detection of the appropriate environmental cues.
IP Status
Patent pending
